The Technical Analyst
VYNE Therapeutics Inc. [VYNE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
VYNE Therapeutics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.40% $2.48
America/New_York / 26 apr 2024 @ 13:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 34.97 mill |
| EPS: | -2.72 |
| P/E: | -0.910 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 14.10 mill |
| Avg Daily Volume: | 0.108 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.910 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -0.910 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.69 (8.56%) $0.212 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.29 - 2.74 ( +/- 8.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Zeronda Tyler | Sell | 94 | Common Stock |
| 2024-04-01 | Stuart Iain | Sell | 157 | Common Stock |
| 2024-04-01 | Harsch Mutya | Sell | 161 | Common Stock |
| 2024-04-01 | Domzalski David | Sell | 1 004 | Common Stock |
| 2024-01-01 | Zeronda Tyler | Buy | 62 500 | Common Stock |
| INSIDER POWER |
|---|
| -56.79 |
| Last 99 transactions |
| Buy: 3 356 313 | Sell: 7 897 303 |
Forecast:
15:34 - $2.46
Live Trading Signals (every 1 min)
Forecast
1: 14:04 - $2.52
Forecast 2: 14:54 - $2.41
Forecast 3: 15:34 - $2.46
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.48 (0.40% ) |
| Volume | 0.0107 mill |
| Avg. Vol. | 0.108 mill |
| % of Avg. Vol | 9.97 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VYNE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VYNE
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Latest Press Releases
2024-03-19 08:00:00 - Press Release
Vyne Therapeutics To Participate In The H.c. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Bridgewater, n.j., march 19, 2024 (globe newswire) -- vyne therapeutics inc. (nasdaq: vyne) (“vyne” or the “company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that david domzalski, president and chief executive officer, and dr. iain stuart, chief scientific officer, will participate in a fireside chat at the h.c. wainwright 2nd annual autoimmune & inflammatory disease virtual conference (skin diseases, conditions and disorders) being held on thursday, march 28, 2024.
2024-02-29 08:00:00 - Press Release
Vyne Reports 2023 Fourth Quarter And Year-end Financial Results And Provides Business Update
Bridgewater, n.j., feb. 29, 2024 (globe newswire) -- vyne therapeutics inc. (nasdaq: vyne) (“vyne” or the “company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended december 31, 2023 and provided a business update.
2024-02-27 08:00:00 - Press Release
Vyne Therapeutics To Present Results Of The Phase 1b Trial For Vyn201 At The 2024 Global Vitiligo Foundation Annual Scientific Symposium
Bridgewater, n.j., feb. 27, 2024 (globe newswire) -- vyne therapeutics inc. (nasdaq: vyne) (“vyne” or the “company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that dr. iain stuart, chief scientific officer of the company, will deliver an oral presentation featuring positive data from the phase 1b trial of vyn201 in vitiligo at the 2024 global vitiligo foundation annual scientific symposium taking place in san diego on march 7, 2024.
2024-02-21 08:00:00 - Press Release
Vyne Therapeutics To Participate In The Td Cowen 44th Annual Health Care Conference
Bridgewater, n.j., feb. 21, 2024 (globe newswire) -- vyne therapeutics inc. (nasdaq: vyne) (“vyne” or the “company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that david domzalski, president and chief executive officer, will participate in a fireside chat at the td cowen 44th annual health care conference at the boston marriott copley place in boston, massachusetts, on march 4, 2024. management will also be available for 1-on-1 meetings with investors.
2024-01-10 08:00:00 - Press Release
Vyne Therapeutics Announces Positive Biomarker Data From Successful Phase 1b Trial Of Vyn201 For The Treatment Of Vitiligo
Bridgewater, n.j., jan. 10, 2024 (globe newswire) -- vyne therapeutics inc. (nasdaq: vyne) (“vyne” or the “company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced new biomarker data from the previously completed phase 1b trial in patients with nonsegmental vitiligo. the data show that bet inhibitor, vyn201, had a positive effect on multiple disease-associated biomarkers.
Latest News
2024-03-19 08:00:00 - GlobeNewsWire
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.
2024-03-13 10:56:27 - Zacks Investment Research
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for VYNE Therapeutics Inc. (VYNE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2024-03-08 13:01:10 - Zacks Investment Research
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
VYNE Therapeutics Inc. (VYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-09-06 08:00:00 - GlobeNewsWire
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Management will also be available for 1-on-1 meetings with investors.
2023-04-20 12:57:34 - Zacks Investment Research
VYNE Gains on Preclinical Data for IPF Candidate
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
2023-04-19 10:32:41 - PennyStocks
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-04-16 06:30:42 - InvestorPlace
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.
2023-03-22 08:00:00 - GlobeNewsWire
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference
BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference being held on Thursday, March 30, 2023. Management will also be available for 1-on-1 meetings with investors.
2022-11-18 08:00:00 - GlobeNewsWire
VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, and management will host investor meetings on December 1, 2022.
2022-11-10 18:48:32 - Zacks Investment Research
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?